Medivir Ab

Medivir Aktiebolag

Medivir UK Ltd

Björn Klasson

Mark Albertella

Fredrik Öberg

John Öhd

Anders Eneroth

Pia Kahnberg

Urszula Grabowska

Peter Tomas Lind

Susana Ayesa

Lourdes Odén

Richard Bethell

Daniel Jönsson

Ellen Hewitt

Daniel Wiktelius

Pedro Pinho

Stina Lundgren

Karolina Ersmark

Kevin Parkes

Lourdes Odèn

Jan Tejbrant

Richard Bethel

Compounds of the formula I wherein X is a bond or —CH, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine resistance and/or over 60 years of age.

Base-modified cytidine nucleotides for leukemia therapy

The invention provides a compound of formula (I)

Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C-Cstraight or branched chain alkyl, X is H, halo, C-Ccycloalkyl or C-Calkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.

Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancer

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C-Cstraight or branched chain alkyl, X is H, halo, C-Ccycloalkyl or C-Calkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis. 

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Cysteine protease inhibitors

Growing community of inventors

Huddinge, Sweden

Björn Klasson